Background
Novartis AG markets Gilenya®, a drug containing fingolimod approved for treating multiple sclerosis. The compound fingolimod is claimed in Novartis’s U.S. Patent No. 5,604,229 (the ‘229 patent), which was filed before the Uruguay Round Agreements Act of 1994 (URAA) took effect. Because it was a pre-URAA patent, its term was calculated as 17 years from issuance — a different formula than the 20-years-from-filing term that applies to post-URAA patents. Novartis also obtained a patent term extension (PTE) of approximately five years under 35 U.S.C. § 156, which compensates patentees for time lost during FDA regulatory review.
Ezra Ventures LLC filed an Abbreviated New Drug Application (ANDA) seeking approval for a generic version of Gilenya and challenged the ‘229 patent’s validity. Ezra argued that a related Novartis patent that was filed after the ‘229 patent but issued with a 20-year post-URAA term constituted an obviousness-type double patenting (OTDP) reference that should limit the ‘229 patent’s term — eliminating the benefit of Novartis’s patent term extension.
The district court sided with Novartis, and Ezra appealed.
The Court’s Holding
The Federal Circuit affirmed. The court began by reaffirming that obviousness-type double patenting is a judicially created doctrine — not a statutory requirement — designed to prevent patentees from extending patent protection beyond what Congress authorized by claiming obvious variations in successive patents. The doctrine’s purpose is to prevent extension of a patent beyond the statutory time limit.
The court held that applying OTDP to eliminate a patent term extension would produce exactly the opposite of its intended purpose: it would use a judge-made doctrine to cut off a congressionally authorized term extension. Congress expressly enacted 35 U.S.C. § 156 to extend patent terms for time lost during FDA review. Allowing a judicially created equitable doctrine to override a statutory grant would be inconsistent with the hierarchy between judge-made rules and acts of Congress.
The court distinguished a prior Federal Circuit case, Gilead Sciences v. Natco Pharma, which had allowed OTDP to apply in different circumstances. Gilead addressed a situation where a later-expiring patent was later-expiring because of how patent terms fell naturally under the URAA transition — not because of a statutory PTE. The court held that Gilead did not control where the additional term resulted from a congressionally granted extension.
Key Takeaways
- Obviousness-type double patenting, a judicially created doctrine, cannot be used to curtail a patent term extension (PTE) that was lawfully granted under 35 U.S.C. § 156 to compensate for FDA regulatory delay.
- Pre-URAA patents with the 17-years-from-issuance term plus a Hatch-Waxman PTE are not vulnerable to OTDP attacks from later-expiring post-URAA patents where the extended term is the result of the statutory PTE.
- The decision protects pharma patentees who lawfully obtain PTEs from having that extra term eliminated by generic challengers invoking OTDP.
- Patent portfolio managers should be aware that OTDP analysis depends on the source of any extended term — naturally longer terms and statutory extensions may be treated differently.
Why It Matters
Novartis v. Ezra Ventures is a significant decision in pharmaceutical patent law because it resolves a creative but potentially devastating challenge to branded drug patents: the argument that a related patent in the same portfolio imposes a terminal disclaimer-like limit on the first patent’s statutory extension. Had the Federal Circuit accepted Ezra’s theory, patent term extensions — which can be worth hundreds of millions of dollars to pharmaceutical companies — would have been vulnerable to elimination through OTDP challenges based on family member patents.
The ruling reinforces the principle that the Hatch-Waxman Act’s PTE mechanism is a statutory right that cannot be taken away by judge-made doctrines. For generic manufacturers, the decision closes off one avenue of challenge while still leaving open challenges based on obviousness, written description, and other statutory grounds. For innovators, it provides reassurance that PTEs obtained for patented drug compounds are durable and cannot be undermined by the structure of the patent family.